|
| Thursday, 4 March 2021, 08:12 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, Mar 4, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has decided to assent to and support a project led by CA Medlynks Kenya, Ltd., a subsidiary of the healthcare startup company engaged in improving healthcare access in Africa, Connect Afya Co., Ltd., which aims to build a new structure for the efficient testing framework for the novel coronavirus infection in Kenya. CA Medlynks Kenya, Ltd., in collaboration with the government of Meru County in Kenya, will support the setup of PCR testing laboratories, along with procurement of equipment necessary for testing and training of screening technicians.
Meru County, one of Kenya's 47 counties, is the most populous county in the Eastern Province of Kenya with approximately 1.35 million people. As the novel coronavirus infection spreads in Kenya, one issue in Meru County is the time required to receive screening results as samples must be sent across over 200 kilometers to the capital city of Nairobi for testing, a situation which is caused by a lack of equipment, facilities and technicians necessary for screening of the novel coronavirus. It is expected that support for this effort will contribute largely to the formation of accurate and rapid understanding of the infection situation as well as strategy that is based on that understanding by construction of PCR testing in Meru County.
Eisai has committed the equivalent of 1 million USD in aid over the span of 1 year in order to support the controlling of the spread of the novel coronavirus infection in Africa, along with prevention of delays of elimination activities for neglected tropical diseases (NTDs). As part of this support, Eisai has begun provision of Personal Protection Equipment (masks, goggles, face shields, etc.) to core hospitals in Africa for research of and countermeasures against infectious diseases, as well as masks and sanitizer for the resuming of mass drug administrations in Kenya for the elimination of NTDs. In addition, Eisai is supporting Amref Health Africa in the development and popularization of its mobile health platform LEAP for healthcare workers in sub-Saharan countries.
Through this support, including the new support for Connect Afya, Eisai will continue in its contribution to mitigating the spread of the novel coronavirus infection in Kenya and other African countries.
About Connect Afya Co., Ltd. and CA Medlynks Kenya, Ltd.
Connect Afya Co., Ltd. (Headquarters: Hyogo, Japan, CEO: Yoichi Shimada) and its local affiliate CA Medlynks Kenya Ltd. (Location: Nairobi are startups delivering clinical laboratory services and providing in-vitro diagnostic medical equipment, for the realization of a society where people enjoy better lives without suffering from limitations of insufficient medical infrastructure.
As of February 2021, the startup has supplied diagnostic services and in-vitro diagnostic medical equipment, including novel coronavirus infection reverse transcription PCR screening equipment, to over thirty healthcare organizations, clinics, and corporations across Kenya.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| May 14, 2021 16:48 HKT/SGT |
|
Eisai and National Cancer Center Commence Joint Research and Development Project |
| May 11, 2021 09:00 HKT/SGT |
|
Eisai's Statement of Commitment for Carbon Neutrality by 2040 |
| May 7, 2021 10:08 HKT/SGT |
|
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications |
| Apr 28, 2021 11:33 HKT/SGT |
|
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan |
| Apr 23, 2021 13:55 HKT/SGT |
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan |
| Apr 23, 2021 12:02 HKT/SGT |
|
Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies |
| Apr 23, 2021 08:07 HKT/SGT |
|
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease |
| Apr 20, 2021 08:23 HKT/SGT |
|
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease |
| Apr 14, 2021 12:49 HKT/SGT |
|
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting |
| Apr 12, 2021 12:16 HKT/SGT |
|
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021 |
| More news >> |
 |
|
|
|
